Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients

Circulation

Volumn 116, Issue 10, 2007, Pages 1137-1144

  Ruan, Yanfei ^a   Liu, Nian ^a   Bloise, Raffaella ^a   Napolitano, Carlo ^a   Priori, Silvia G ^a,b  

^a IRCCS   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Electrophysiology; Genetics; Ion channels; Long QT syndrome; Pharmacology; Sodium

Indexed keywords

MEXILETINE; SODIUM CHANNEL;

ARTICLE; BIOPHYSICS; CHANNEL GATING; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; SODIUM CURRENT;

ADULT; CHILD; CHILD, PRESCHOOL; GENE THERAPY; HUMANS; INFANT; ION CHANNEL GATING; LONG QT SYNDROME; MEXILETINE; MUSCLE PROTEINS; MUTATION; SODIUM CHANNELS;

EID: 34548378735     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.707877     Document Type: Article

References (23)

1. George AL Jr. Inherited disorders of voltage-gated sodium channels. J Clin Invest. 2005;115:1990-1999.
2. + channel blockade and to increases in heart rate: IMPLICATIONS for gene-specific therapy. Circulation. 1995;92:3381-3386.
3. + channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome. Circ Res. 1996;78:1009-1015.
4. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini A, Spazzolini C, Nastoli J, Bottelli G, Folli R, Cappelletti D. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866-1874.
5. Schwartz PJ, Priori SG, Dumaine R, Napolitano C, Antzelevitch C, Stramba-Badiale M, Richard TA, Berti MR, Bloise R. A molecular link between the sudden infant death syndrome and the long-QT syndrome. N Engl J Med. 2000;343:262-267.
6. Schwartz P, Priori S. Long QT syndrome: genotype-phenotype correlations. In: Zipes D, Jalife J, eds. Cardiac Electrophysiolgy: From Cell to Bedside. Philadelphia, Pa: WB Saunders Co; 2004:651-659.
7. Rivolta I, Clancy CE, Tateyama M, Liu H, Priori SG, Kass RS. A novel SCN5A mutation associated with long QT-3: altered inactivation kinetics and channel dysfunction. Physiol Genomics. 2002;10:191-197.
8. Wang DW, Yazawa K, Makita N, George AL Jr, Bennett PB. Pharmacological targeting of long QT mutant sodium channels. J Clin Invest. 1997;99:1714-1720.
9. Weckbecker K, Wurz A, Mohammadi B, Mansuroglu T, George AL Jr, Lerche H, Dengler R, Lehmann-Horn F, Mitrovic N. Different effects of mexiletine on two mutant sodium channels causing paramyotonia congenita and hyperkalemic periodic paralysis. Neuromuscul Disord. 2000;10:31-39.
10. Bean BP, Cohen CJ, Tsien RW. Lidocaine block of cardiac sodium channels. J Gen Physiol. 1983;81:613-642.
11. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103:89-95.
12. Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, Moncalvo C, Tulipani C, Veia A, Bottelli G, Nastoli J. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292:1341-1344.
13. Benhorin J, Taub R, Goldmit M, Kerem B, Kass RS, Windman I, Medina A. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation. 2000;101:1698-1706.
14. Callaham ML, Wears RL, Weber EJ, Barton C, Young G. Positive-outcome bias and other limitations in the outcome of research abstracts submitted to a scientific meeting. JAMA. 1998;280:254-257.
15. Kambouris NG, Nuss HB, Johns DC, Marban E, Tomaselli GF, Balser JR. A revised view of cardiac sodium channel "blockade" in the long-QT syndrome. J Clin Invest. 2000;105:1133-1140.
16. Desaphy JF, De Luca A, Tortorella P, De Vito D, George AL Jr, Conte Camerino D. Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative. Neurology. 2001;57:1849-1857.
17. Smits JP, Veldkamp MW, Bezzina CR, Bhuiyan ZA, Wedekind H, Schulze-Bahr E, Wilde AA. Substitution of a conserved alanine in the domain IIIS4-S5 linker of the cardiac sodium channel causes long QT syndrome. Cardiovasc Res. 2005;67:459-466.
18. Schulze-Bahr E, Fenge H, Etzrodt D, Haverkamp W, Monnig G, Wedekind H, Breithardt G, Kehl HG. Long QT syndrome and life threatening arrhythmia in a newborn: molecular diagnosis and treatment response. Heart. 2004;90:13-16.
19. Kehl HG, Haverkamp W, Rellensmann G, Yelbuz TM, Krasemann T, Vogt J, Schulze-Bahr E. Images in cardiovascular medicine. Life-threatening neonatal arrhythmia: successful treatment and confirmation of clinically suspected extreme long QT-syndrome-3. Circulation. 2004;109:e205-206.
20. + channel. J Physiol. 2004;561:39-51.
21. Wang DW, Desai RR, Crotti L, Arnestad M, Insolia R, Pedrazzini M, Ferrandi C, Vege A, Rognum T, Schwartz PJ, George AL Jr. Cardiac sodium channel dysfunction in sudden infant death syndrome. Circulation. 2007;115:368-376.
22. Kass RS, Moss AJ. Mutation-specific pharmacology of the long QT syndrome. Handb Exp Pharmacol. 2006;171:287-304.
23. + channel implicate the selectivity filter as a structural determinant of antiarrhythmic drug access. Mol Pharmacol. 2004;66:330-336.